206 related articles for article (PubMed ID: 33876699)
1. Protective antibodies against human parainfluenza virus type 3 infection.
Boonyaratanakornkit J; Singh S; Weidle C; Rodarte J; Bakthavatsalam R; Perkins J; Stewart-Jones GBE; Kwong PD; McGuire AT; Pancera M; Taylor JJ
MAbs; 2021; 13(1):1912884. PubMed ID: 33876699
[TBL] [Abstract][Full Text] [Related]
2. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S
J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977
[TBL] [Abstract][Full Text] [Related]
3. Influence of antigen insertion site and vector dose on immunogenicity and protective capacity in Sendai virus-based human parainfluenza virus type 3 vaccines.
Mason JN; Elbahesh H; Russell CJ
J Virol; 2013 May; 87(10):5959-69. PubMed ID: 23514887
[TBL] [Abstract][Full Text] [Related]
4. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
[TBL] [Abstract][Full Text] [Related]
5. The aberrant gene-end transcription signal of the matrix M gene of human parainfluenza virus type 3 downregulates fusion F protein expression and the F-specific antibody response in vivo.
Lingemann M; Surman S; Amaro-Carambot E; Schaap-Nutt A; Collins PL; Munir S
J Virol; 2015 Mar; 89(6):3318-31. PubMed ID: 25589643
[TBL] [Abstract][Full Text] [Related]
6. T-Cell Therapeutics Targeting Human Parainfluenza Virus 3 Are Broadly Epitope Specific and Are Cross Reactive With Human Parainfluenza Virus 1.
Harris KM; Horn SE; Grant ML; Lang H; Sani G; Jensen-Wachspress MA; Kankate VV; Datar A; Lazarski CA; Bollard CM; Keller MD
Front Immunol; 2020; 11():575977. PubMed ID: 33123159
[TBL] [Abstract][Full Text] [Related]
7. Human parainfluenza virus 3 vaccine candidates attenuated by codon-pair deoptimization are immunogenic and protective in hamsters.
Afroz S; Saul S; Dai J; Surman S; Liu X; Park HS; Le Nouën C; Lingemann M; Dahal B; Coleman JR; Mueller S; Collins PL; Buchholz UJ; Munir S
Proc Natl Acad Sci U S A; 2024 Jun; 121(25):e2316376121. PubMed ID: 38861603
[TBL] [Abstract][Full Text] [Related]
8. Human parainfluenza virus-3 can be targeted by rapidly ex vivo expanded T lymphocytes.
McLaughlin LP; Lang H; Williams E; Wright KE; Powell A; Cruz CR; Colberg-Poley AM; Barese C; Hanley PJ; Bollard CM; Keller MD
Cytotherapy; 2016 Dec; 18(12):1515-1524. PubMed ID: 27692559
[TBL] [Abstract][Full Text] [Related]
9. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
Liang B; Surman S; Amaro-Carambot E; Kabatova B; Mackow N; Lingemann M; Yang L; McLellan JS; Graham BS; Kwong PD; Schaap-Nutt A; Collins PL; Munir S
J Virol; 2015 Sep; 89(18):9499-510. PubMed ID: 26157122
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting Human Parainfluenza Virus Infection by Preactivating the Cell Entry Mechanism.
Bottom-Tanzer SF; Rybkina K; Bell JN; Alabi CA; Mathieu C; Lu M; Biswas S; Vasquez M; Porotto M; Melero JA; Más V; Moscona A
mBio; 2019 Feb; 10(1):. PubMed ID: 30782664
[TBL] [Abstract][Full Text] [Related]
11. Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections.
Zhan X; Slobod KS; Krishnamurthy S; Luque LE; Takimoto T; Jones B; Surman S; Russell CJ; Portner A; Hurwitz JL
Vaccine; 2008 Jun; 26(27-28):3480-8. PubMed ID: 18499307
[TBL] [Abstract][Full Text] [Related]
12. Genetic analyses of the fusion protein genes in human parainfluenza virus types 1 and 3 among patients with acute respiratory infections in Eastern Japan from 2011 to 2015.
Tsutsui R; Tsukagoshi H; Nagasawa K; Takahashi M; Matsushima Y; Ryo A; Kuroda M; Takami H; Kimura H
J Med Microbiol; 2017 Feb; 66(2):160-168. PubMed ID: 28266286
[TBL] [Abstract][Full Text] [Related]
13. Effects of Alterations to the CX3C Motif and Secreted Form of Human Respiratory Syncytial Virus (RSV) G Protein on Immune Responses to a Parainfluenza Virus Vector Expressing the RSV G Protein.
Liang B; Kabatova B; Kabat J; Dorward DW; Liu X; Surman S; Liu X; Moseman AP; Buchholz UJ; Collins PL; Munir S
J Virol; 2019 Apr; 93(7):. PubMed ID: 30651356
[TBL] [Abstract][Full Text] [Related]
14. Potent HPIV3-neutralizing IGHV5-51 Antibodies Identified from Multiple Individuals Show L Chain and CDRH3 Promiscuity.
Abu-Shmais AA; Miller RJ; Janke AK; Wolters RM; Holt CM; Raju N; Carnahan RH; Crowe JE; Mousa JJ; Georgiev IS
J Immunol; 2024 May; 212(9):1450-1456. PubMed ID: 38488511
[TBL] [Abstract][Full Text] [Related]
15. Mapping of an antigenic site on the nucleocapsid protein of human parainfluenza virus type 3.
Zvirbliene A; Sezaite I; Pleckaityte M; Kucinskaite-Kodze I; Juozapaitis M; Sasnauskas K
Viral Immunol; 2009 Jun; 22(3):181-8. PubMed ID: 19435414
[TBL] [Abstract][Full Text] [Related]
16. A chimeric glycoprotein formulated with a combination adjuvant induces protective immunity against both human respiratory syncytial virus and parainfluenza virus type 3.
Garg R; Brownlie R; Latimer L; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
Antiviral Res; 2018 Oct; 158():78-87. PubMed ID: 30071204
[TBL] [Abstract][Full Text] [Related]
17. Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate.
Liang B; Ngwuta JO; Surman S; Kabatova B; Liu X; Lingemann M; Liu X; Yang L; Herbert R; Swerczek J; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Collins PL; Munir S
J Virol; 2017 Aug; 91(15):. PubMed ID: 28539444
[TBL] [Abstract][Full Text] [Related]
18. A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV.
Liang B; Matsuoka Y; Le Nouën C; Liu X; Herbert R; Swerczek J; Santos C; Paneru M; Collins PL; Buchholz UJ; Munir S
J Virol; 2020 Dec; 95(2):. PubMed ID: 33115876
[TBL] [Abstract][Full Text] [Related]
19. Development of a novel subunit vaccine that protects cotton rats against both human respiratory syncytial virus and human parainfluenza virus type 3.
Homa FL; Brideau RJ; Lehman DJ; Thomsen DR; Olmsted RA; Wathen MW
J Gen Virol; 1993 Sep; 74 ( Pt 9)():1995-9. PubMed ID: 8397289
[TBL] [Abstract][Full Text] [Related]
20. Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates.
Liu X; Liang B; Liu X; Amaro-Carambot E; Surman S; Kwong PD; Graham BS; Collins PL; Munir S
PLoS One; 2020; 15(2):e0228572. PubMed ID: 32045432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
